Please assess the completion status of the following clinical trial:

Trial Title: Chloroprocaine 3% - Epidural Anesthesia in Unplanned Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent: Signed written informed consent before inclusion in the study (obtained from women fulfilling the criteria, only when effective analgesia has been established)~2. Sex, pregnancy status and age: Labouring women with singleton pregnancy, ≥ 18 years old~3. Epidural catheter: Previously sited epidural catheter~4. ASA physical status: I-II~5. Analgesia: Effective analgesia established following combined spinal epidural analgesia (CSE)~6. Term gestation: ≥ 36 weeks~7. Caesarean section: Unplanned Caesarean section category 2 or 3, according to Lucas Classification~8. Body Mass Index (BMI): ≤ 40 kg/m2~9. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study.~Exclusion Criteria:~1. Physical findings: Clinically significant abnormal physical findings which could interfere with the objectives of the study. Contraindications to epidural anaesthesia~2. ASA physical status: III-V~3. Further anaesthesia: Patients expected to require further anaesthesia~4. Epidural catheter: Epidural catheter failure (epidural catheter replacement required or inability to provide effective analgesia)~5. Pregnancy: Labouring women with multiple pregnancy~6. Caesarean section: Elective Caesarean section~7. Allergy: ascertained or presumptive hypersensitivity to the active principle and /or formulations ingredients; ascertained or presumptive hypersensitivity to the amide and ester-type anaesthetics~8. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric diseases, eclampsia, antepartum haemorrhage, sepsis, blood coagulation disorders, insulin dependent diabetes mellitus, terminal kidney failure~9. Medications: Medication known to interfere with the extent of regional blocks (see chloroprocaine and ropivacaine SmPCs) for 2 weeks before the start of the study~10. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study~11. Drug, alcohol: history of drug or alcohol abuse~12. Plasma cholinesterase: Known plasma cholinesterase deficiency.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroprocaine (Type: EXPERIMENTAL): Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
- Ropivacaine (Type: ACTIVE_COMPARATOR): Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues